FDA Panel Backs Moderna mRNA Flu Vaccine For Older Adults
2h
Developing
1
An FDA advisory panel unanimously concluded Thursday that Moderna's mRNA seasonal flu vaccine candidate, mFlusiva, has benefits that outweigh risks for adults 50 and older. PBS News
